15.00
-0.07 (-0.46%)
| Previous Close | 15.07 |
| Open | 15.42 |
| Volume | 1,588,680 |
| Avg. Volume (3M) | 877,569 |
| Market Cap | 833,950,528 |
| Price / Earnings (TTM) | 13.39 |
| Price / Sales | 3.24 |
| Price / Book | 2.87 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | CareDx, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.11% |
| % Held by Institutions | 99.34% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Stephens & Co., 166.67%) | Buy |
| Median | 26.00 (73.33%) | |
| Low | 25.00 (HC Wainwright & Co., 66.67%) | Hold |
| Average | 30.33 (102.20%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 15.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 May 2025 | 25.00 (66.67%) | Hold | 15.17 |
| Stephens & Co. | 05 May 2025 | 40.00 (166.67%) | Buy | 15.17 |
| Goldman Sachs | 17 Apr 2025 | 26.00 (73.33%) | Buy | 17.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Jun 2025 | Announcement | CareDx Announces Repurchase of 5% of Outstanding Shares |
| 13 May 2025 | Announcement | CareDx to Participate in Upcoming Investor Conferences |
| 30 Apr 2025 | Announcement | CareDx Reports First Quarter 2025 Results |
| 29 Apr 2025 | Announcement | CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting |
| 24 Apr 2025 | Announcement | CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting |
| 21 Apr 2025 | Announcement | CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
| 08 Apr 2025 | Announcement | CareDx to Report First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |